De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation

Metabolic dysfunction-associated fatty liver disease(MAFLD)is a new acronym adopted from the consensus of international experts.Given the increasing prevalence of MAFLD in pre-transplant settings,de novo and recurrent graft steatosis/MAFLD are common in post-transplant settings.The impact of graft steatosis on long-term outcomes is unclear.The current knowledge of incidence rate,risk factors,diagnosis,long-term outcomes,and management of graft steatosis(both de novo and recurrent)is discussed in this review.